ARCHIVES

Combined analysis moves Herceptin to adjuvant setting in breast cancer.

This article is from The Cancer Letter archive.

Vol. 31 No. 21 | May 27, 2005

Download PDF Visit The Full Archive

Related Articles

Five Contracts Funded Under Unconventional Innovations Program

October 22, 1999

Study: Blood Test More Accurate Than Traditional Tumor Biopsy

April 26, 2013

Risk-Benefit Analysis Advised Prior To Hormone Therapy

August 27, 2010

ASCO Picks University of Michigan Medical School Dean Allen Lichter As Exective Vice President and CEO.

July 14, 2006

Levamisole/5-FU Could Save $226 Mil. If Fully Adopted, NCI Economist Says

April 20, 1990

NIH Seeks Comment On Reorg Plan For Oncology Study Sections

April 5, 2002